NaPro's unorthodox monetizing play
On its face, NaPro BioTherapeutics Inc.'s decision to sell its one approved product, a generic version of paclitaxel, flies in the face of conventional wisdom, as the company unloaded its revenue stream and morphed into a preclinical play. But a single generic drug does not make for a
